ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

Atherosclerosis

Volumn 217, Issue 1, 2011, Pages 3-46

  Catapano, Alberico L ^a   Reiner, Željko ^a   De Backer, Guy ^a   Graham, Ian ^a   Taskinen, Marja Riitta ^a   Wiklund, Olov ^a   Agewall, Stefan ^a   Alegria, Eduardo ^a   Chapman, M John ^a   Durrington, Paul ^a   Erdine, Serap ^a   Halcox, Julian ^a   Hobbs, Richard ^a   Kjekshus, John ^a   Perrone Filardi, Pasquale ^a   Riccardi, Gabriele ^a   Storey, Robert F ^a   Wood, David ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cardiovascular diseases; Cholesterol; Dyslipidaemia; Guidelines; Treatment; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; BEZAFIBRATE; BILE ACID SEQUESTRANT; CALCINEURIN INHIBITOR; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CIPROFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CORTICOSTEROID; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ACETYLSALICYLIC ACID; ANACETRAPIB; CLOPIDOGREL; DALCETRAPIB; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INSULIN; MEVINOLIN; MIPOMERSEN; TORCETRAPIB;

ABDOMINAL AORTA ANEURYSM; ACANTHOSIS NIGRICANS; ACUTE CORONARY SYNDROME; ACUTE PANCREATITIS; ALCOHOL CONSUMPTION; AORTA SURGERY; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARBOHYDRATE INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIALYSIS; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG FATALITY; DRUG METABOLISM; DYSLIPIDEMIA; DYSPEPSIA; ERRATUM; EVENING DOSAGE; FAMILIAL HYPERCHOLESTEROLEMIA; FAT INTAKE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GENOTYPE; GLUCOSE METABOLISM; HEART FAILURE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRANSAMINASEMIA; HYPERURICEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; KIDNEY DISEASE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIVER FAILURE; LIVER TOXICITY; LUNG EMBOLISM; MEDICAL SOCIETY; METABOLIC SYNDROME X; MONOTHERAPY; MORNING DOSAGE; MYALGIA; MYOPATHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PARTICLE SIZE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PRURITUS; RHABDOMYOLYSIS; SCREENING; SECONDARY PREVENTION; SIDE EFFECT; STROKE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; ABSENCE OF SIDE EFFECTS; ACUTE HEMORRHAGIC PANCREATITIS; AGE; ALZHEIMER DISEASE; BLEEDING; BODY WEIGHT; CARBOHYDRATE DIET; CHOLESTEROL METABOLISM; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DIETARY FIBER; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FAMILY HISTORY; FLUSHING; GLUCOSE BLOOD LEVEL; HYPERTRIGLYCERIDEMIA; ISCHEMIC CARDIOMYOPATHY; KINESIOTHERAPY; LOW DRUG DOSE; LUNG DISEASE; MULTIPLE SCLEROSIS; NUTRITION; OBESITY; PATIENT MONITORING; PHENOTYPE; PHYSICAL ACTIVITY; RASH; REVIEW; SEX DIFFERENCE; SMOKING; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; ATHEROSCLEROSIS; CARDIOLOGY; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; DYSLIPIDEMIAS; EUROPE; FEMALE; GENOTYPE; HUMANS; LIFE STYLE; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 79960205374     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.06.028     Document Type: Review

References (224)

1. Allender S, Scarborough P, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European cardiovascular disease statistics, 2008 ed. European Heart Network, 2008.
2. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology European Atherosclerosis Society European Society of Hypertension. Atherosclerosis 1994, 110:121-161.
3. Wood D., De Backer G., Faergeman O., et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998, 19:1434-1503.
4. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003, 10:S1-S78.
5. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: Fourth Joint Task Force of the European Society of Cardiology and other societies. Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl. 2):S1-S113.
6. Cooney M.T., Dudina A.L., Graham I.M. Value and limitations of existing scores for the assessment of cardiovascular risk. A review for clinicians. J Am Coll Cardiol 2009, 54:1209-1227.
7. Cooney M.T., Dudina A., d'Agostino R., Graham I.M. Cardiovascular risk estimation systems in primary prevention. Do they differ? Do they make a difference? Can we see the future?. Circulation 2010, 122:300-310.
8. Conroy R., Pyorala K., Fitzgerald A.P., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003, 24:987-1003.
9. D'Agostino R.B., Vasan R.S., Pencina M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743-753.
10. Cooney M., Dudina A., Bacquer D.D., et al. How much does HDL cholesterol add to risk estimation? A report from the SCORE investigators. Eur J Cardiovasc Prev Rehabil 2009, 16:304-314.
11. Cooney M.T., Dudina A., De Bacquer D., et al. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis 2009, 206:611-616.
12. Bansal S., Buring J.E., Rifai N., et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
13. Bassand J.P., Hamm C.W., Ardissino D., et al. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007, 28:1598-1660.
14. Van de Werf F., Bax J., Betriu A., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008, 29:2909-2945.
15. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
16. Brugts J.J., Yetgin T., Hoeks S.E., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009, 338:b2376.
17. Mills E.J., Rachlis B., Wu P., et al. Primary prevention of cardiovascular mortality and events with statin treatments. A network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008, 52:1769-1781.
18. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389. Scandinavian Simvastatin Survival Study Group.
19. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
20. Lewis S.J., Moye L.A., Sacks F.M., et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998, 129:681-689.
21. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615-1622.
22. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group.
23. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
24. Serruys P.W., de Feyter P., Macaya C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 287:3215-3222.
25. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360:7-22.
26. Shepherd J., Blauw G.J., Murphy M.B., et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
27. Holdaas H., Fellström B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024-2031.
28. Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than-average cholesterol concentrations, in the ANGLO-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
29. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
30. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307-1316.
31. Wanner C., Krane V., März W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
32. Pedersen T.R., Faergeman O., Kastelein J.J., et al. High dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445.
33. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
34. Amarenco P., Bogousslavsky J., Callahan A., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549-559.
35. Ray K.K., Cannon C.P., McCabe C.H., et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005, 46:1405-1410.
36. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
37. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
38. Rossebø A.B., Pedersen T.R., Boman K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356.
39. Investigators Gissi-HF., Tavazzi L., Maggioni A.P., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239.
40. Fellström B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
41. Taylor F., Ward K., Moore T.H., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011, 1:CD00481642.
42. The Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000.
43. Langsted A., Freiberg J.J., Nordestgaard B.G. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008, 118:2047-2056.
44. Robinson J.G., Wang S., Smith B.J., Jacobson T.A. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009, 53:316-322.
45. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
46. Charlton-Menys V., Betteridge D.J., Colhoun H., et al. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem 2009, 55:473-480.
47. Taskinen M.R., Barter P.J., Ehnholm C., et al. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia 2010, 53:1846-1855. on behalf of the FIELD Study Investigators.
48. Sniderman A.D., Williams K., Contois J.H., et al. Meta-analysis of LDL-C, non-HDL-C and apo B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011, 4:337-345.
49. Erqou S., Kaptoge S., Perry P.L., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423.
50. Marcovina S.M., Koschinsky M.L., Albers J.J., Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions. Clin Chem 2003, 49:1785-1796.
51. Nordestgaard B.G., Chapman J., Ray K., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31:2844-2853. for the European Atherosclerosis Society Consensus Panel.
52. Jun M., Foote C., Lu J., et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1884.
53. Holme I., Cater N.B., Faergeman O., et al. Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL). Ann Med 2008, 40:456-464.
54. Packard C.J. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol 2006, 17:412-417.
55. Mora S., Szklo M., Otvos J.D., et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007, 192:211-217.
56. Drenos F., Whittaker J.C., Humphries S.E. The use of meta-analysis risk estimates for candidate genes in combination to predict coronary heart disease risk. Ann Hum Genet 2007, 71:611-619.
57. Wierzbicki A.S., Humphries S.E., Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008, 337:a1095.
58. Murphy S.A., Cannon C.P., Wiviott S.D., et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol 2007, 100:1047-1051.
59. Ridker P.M., Danielson E., Fonseca F.A.H., et al. Reduction in C-reactive protein and LDL-cholesterol and cardiovascular event rates after intitiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-1182.
60. Hu F., Willett W.C. Optimal diets for prevention of coronary heart disease. JAMA 2002, 288:2569-2578.
61. Grundy S.M. Lipids, nutrition and coronary heart disease. Atherosclerosis and coronary artery disease 1996, Lippincott-Raven, Philadelphia. V. Fuster, R. Ross, E.J. Topol (Eds.).
62. Mente A., de Koning L., Shannon H.S., Anand S.S. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart diseases. Arch Intern Med 2009, 169:659-669.
63. Mensink R.P., Zock P.L., Kester A.D.M., Katan M.B. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003, 77:1146-1155.
64. Mozaffarian D., Aro A., Willett W.C. Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr 2009, 63:S5-S21.
65. Brown L., Rosner B., Willet W., Sacks S.M. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999, 69:30-42.
66. Keys A. Serum cholesterol response to dietary cholesterol. Am J Clin Nutr 1984, 40:351-359.
67. Abumweis SS, Barake R, Jones PJ. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res 2008;52, doi:10.3402/fnr.v52io.1811.
68. Dattilo A.M., Kris-Etherton P.M. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992, 56:320-328.
69. Sirtori C.R., Galli C., Anderson J.W., Arnoldi A. Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: focus on dietary proteins. Atherosclerosis 2009, 203:8-17.
70. Shaw K., Gennat H., O'Rourke P., Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev 2006, 4:CD003817.
71. Becker D.J., Gordon R.Y., Halbert S.C., et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009, 150:830-839.
72. Lu Z., Kou W., Du B., et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008, 101:1689-1693.
73. Berthold H.K., Unverdorben S., Degenhardt R., Bulitta M., Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 2006, 295:2262-2269.
74. Rimm E.B., Williams P., Fosher K., Criqui M., Stampfer M.J. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999, 319:1523-1528.
75. Bantle J.P., Raatz S.K., Thomas W., Georgopoulos A. Effects of dietary fructose on plasma lipids in healthy subjects. Am J Clin Nutr 2000, 72:1128-1134.
76. Stanhope K.L., Schwarz J.M., Keim N.L., et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009, 119:1322-1334.
77. Kraus W.E., Houmard J.A., Duscha B.D., et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002, 347:1483-1492.
78. Nordmann A.J., Nordmann A., Briel M., et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 2006, 166:285-293.
79. Harris W.S. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997, 65(5 Suppl.):S1645-S1654.
80. Beulens J.W., Rimm E., Ascherio A., et al. Alcohol consumption and risk for coronary heart disease among men with hypertension. Ann Intern Med 2007, 146:10-19.
81. Rabkin S.W. Effect of cigarette smoking cessation on risk factors for coronary atherosclerosis. A control clinical trial. Atherosclerosis 1984, 53:173-184.
82. Ordovas J.M. Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention. Am J Clin Nutr 2009, 89:1509S-1517S.
83. NCEP Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
84. Mattar M., Obeid O. Fish oil and the management of hypertriglyceridemia. Nutr Health 2009, 20:41-49.
85. Liu S., Manson J.E., Stampfer M.J., et al. Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women. Am J Clin Nutr 2001, 73:560-566.
86. Mooradian A.D., Haas M.J., Wong N.C. The effect of select nutrients on serum high-density lipoprotein cholesterol and apolipoprotein A-I levels. Endocr Rev 2006, 27:2-16.
87. Kelly S., Frost G., Whittaker V., Summerbell C. Low glycaemic index diets for coronary heart disease. Cochrane Database Syst Rev 2004, 4:CD004467.
88. Process for the assessment of scientific support for claims on foods: consensus on criteria. Eur J Nutr 2005, 44:I/5-I/30. PASSCLAIM.
89. Lea L.J., Hepburn P.A. Safety evaluation of phytosterol-esters. Part 9: results of a European post-launch monitoring programme. Food Chem Toxicol 2006, 44:1213-1222.
90. Dewell A., Hollenbeck P.L., Hollenbeck C.B. A critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. J Clin Endocrinol Metab 2006, 91:772-780.
91. Rideout T.C., Harding S.V., Jones P.J., Fan M.Z. Guar gum and similar soluble fibers in the regulation of cholesterol metabolism: current understandings and future research priorities. Vasc Health Risk Manag 2008, 4:1023-1033.
92. Kromhout D., Giltay E.J., Geleijnse JM n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010, 363:2015-2026. for the Alpha Omega Trial Group.
93. Mas R., Castano G., Illinait J., et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999, 65:439-447.
94. Reiner Z., Tedeschi-Reiner E., Romić Z. Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients. Clin Drug Investig 2005, 25:701-707.
95. Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645.
96. Swain J.F., McCarron P.B., Hamilton E.F., Sacks F.M., Appel L.J. Characteristics of the diet patterns tested in the optimal macronutrient intake trial to prevent heart disease (Omni-Heart): options for a heart-healthy diet. J Am Diet Assoc 2008, 108:257-265.
97. Howard B.V., Van Horn L., Hsia J., et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006, 295:655-666.
98. Harris W.S., Mozaffarian D., Rimm E., et al. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition. Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation 2009, 119:902-907.
99. Poli A., Marangoni F., Paoletti R., et al. Non-pharmacological control of plasma cholesterol levels. Nutr Metab Cardiovasc Dis 2008, 18:S1-S16.
100. Catapano A.L. Perspectives on low-density-lipoprotein cholesterol goal achievement. Curr Med Res Opin 2009, 25:431-447.
101. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010, 375:735-742.
102. Hippisley-Cox J., Coupland C. Unintended effects of statins in men and women in England and Wales: population-based cohort study using the QResearch database. BMJ 2010, 340:c2197.
103. Garcia-Rodriguez L.A., Massó-González E.L., Wallander M.A., Johansson S. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf 2008, 17:943-952.
104. Holoshitz N., Alsheikh-Ali A.A., Karas R.H. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. Am J Cardiol 2008, 101:95-97.
105. Franssen R., Vergeer M., Stroes E.S., Kastelein J.J. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab 2009, 11:89-94.
106. Guyton J.R., Bays H.E. Safety considerations with niacin therapy. Am J Cardiol 2007, 99(Suppl.):22C-31C.
107. Cziraky M.J., Willey V.J., Mckenney J.M., et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006, 97:61C-68C.
108. Tyroler H.A. Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) epidemiologic studies as background for the LRC Coronary Primary Prevention Trial. Am J Cardiol 1984, 54:14C-19C.
109. Levy P. Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus. Metab Syndr Relat Disord 2010, 8(Suppl. 1):S9-S13.
110. Fonseca V.A., Handelsman Y., Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab 2010, 12:384-392.
111. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010, 160:785-794. SHARP Collaborative Group.
112. Chapman M.J., Redfern J.S., McGovern M.E., Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010, 126:314-345.
113. Reiner Ž. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol 2010, 24:19-28.
114. Zhao X.Q., Krasuski R.A., Baer J., et al. Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis treatment study (FATS), the HDL-Atherosclerosis treatment study (HATS) and the Armed Forces regression Study (AFREGS). Am J Cardiol 2009, 104:1457-1464.
115. Huijgen R., Abbink E.J., Bruckert E., et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week multicenter, randomized, double-blind, controlled trial. Clin Ther 2010, 32:615-625.
116. Ballantyne C.M., Weiss R., Moccetti T., et al. Efficacy and safety of rosuvastatin 40mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol 2007, 99:673-680.
117. Cuchel M., Bloedon L.T., Szapary P.O., et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007, 356:148-156.
118. Ladenson P.W., Kristensen J.D., Ridgway E.C., et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidaemia. N Engl J Med 2010, 362:906-916.
119. Raal F.J., Santos R.D., Blom D.J., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006.
120. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
121. Sarwar N., Sandhu M.S., et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration.
122. Kotseva K., Wood D., De Backer G., et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009, 16:121-137.
123. Ewald N., Hardt P.D., Kloer H.U. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol 2009, 20:497-504.
124. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. N Engl J Med 1987, 317:1237-1245.
125. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410-418.
126. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000, 102:21-27. The BIP Study Group.
127. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
128. Davidson M.H., Armani A., McKenney J.M., Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol 2007, 99:3C-18C.
129. Taskinen M.-R., Sullivan D.R., Ehnholm C., et al. Relationships of HDL cholesterol, apoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol 2009, 29:950-955.
130. Kamanna V.S., Kashyap M.L. Mechanism of action of niacin. Am J Cardiol 2008, 101:20B-26B.
131. Bruckert E., Labreuche J., Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010, 210:353-361.
132. Brown B.G., Zhao X.Q. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 2008, 101:58B-62B.
133. Lee J.M., Robson M.D., Yu L.M., et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009, 54:1787-1794.
134. Villines T.C., Stanek E.J., Devine P.J., et al. Final results and the impact of medication adherence, dose and treatment duration. J Am Coll Cardiol 2010, 55:2721-2726.
135. Balk E.M., Lichtenstein A.H., Chung M., et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006, 189:19-30.
136. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
137. Hooper L., Thompson R.L., Harrison R.A., et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 2006, 332:752-760.
138. Marchioli R., Barzi F., Bomba E., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002, 105:1897-1903.
139. Grundy S.M., Vega G.L., Yuan Z., et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidaemia (the SAFARI trial). Am J Cardiol 2005, 95:462-468.
140. Jones P.H., Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin. Am J Cardiol 2005, 95:120-122.
141. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574. The ACCORD Study Group.
142. McKenney J.M., Jones P.H., Bays H.E., et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007, 192:432-437.
143. Guyton J.R., Brown B.G., Fazio S., et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidaemia. J Am Coll Cardiol 2008, 51:1564-1572.
144. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289-1298.
145. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
146. Davidson M.H., Stein E.A., Bays H.E., et al. COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding rescription omega-3 fatty acids 4g/d to simvastatin 40mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007, 29:1354-1367.
147. Saito Y., Yokoyama M., Origasa H., et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008, 200:135-140.
148. The European Atherosclerosis Society Consensus Panel Triglyceride-rich lipoprotein and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011, 32:1345-1361.
149. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007, 297:499-508.
150. Poulter N. The impact of micronized fenofibrate on lipid subfractions and on reaching HDL-target levels in 7,098 patients with dyslipidaemia. Br J Cardiol 1999, 6:682-685.
151. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
152. Fruchart J.C., Sacks F., Hermans M.P., et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008, 102(10 Suppl.):1K-34K.
153. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
154. Veenkamp M.S., de Graaf J., Bredie S.J., et al. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol 2002, 22:274-282.
155. Neil A., Cooper J., Betteridge J., et al. Reductions in all-cause, cancer and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolemia: a prospective registry study. Eur Heart J 2008, 29:2625-2633.
156. DeMott K, Nherera L, Shaw EJ, Minhas R, Humphries SE, Kathoria M, Ritchie G, Nunes V, Davies D, Lee P, McDowell I, Neil A, Qureshi N, Rowlands P, Seed M, Stracey H, Thorogood M, Watson M. Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008.
157. World Health Organization, Human Genetics Programme. Familial hypercholesterolemia: report of a second WHO consultation. WHO/HGN/FH/Cons/99.2. Geneva: WHO; 1999.
158. Defesche J.C., Lansberg P.J., Umans-Eckenhausen M.A., Kastelein J.J. Advanced method for the identification of patients with inherited hypercholesterolemia. Semin Vasc Med 2004, 4:59-65.
159. Humphries S.E., Whittall R.A., Hubbart C.S., et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006, 43:943-949.
160. Whittall R.A., Scartezini M., Li K., et al. Development of a high-resolution melting method for mutation detection in familial hypercholesterolaemia patients. Ann Clin Biochem 2010, 47:44-55.
161. Mehta P.K., Baer J., Nell C., Sperling L.S. Low-density lipoprotein apheresis as a treatment for hyperlipidaemia. Curr Treat Options Cardiovasc Med 2009, 11:279-288.
162. Jonsdottir L.S., Sigfusson N., Gudnason V., Sigvaldason H., Thorgeirsson G. Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. J Cardiovasc Risk 2002, 9:67-76.
163. Petretta M., Costanzo P., Perrone-Filardi P., Chiariello M. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int J Cardiol 2010, 138:25-31.
164. Walsh J.M.E., Pignone M. Drug treatment of hyperlipidaemia in women. JAMA 2004, 291:2243-2252.
165. Shufelt C.L., Bayiey Merz C. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009, 53:221-231.
166. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003, 349:523-534.
167. Gransbo K., Melander O., Wallentin L., et al. Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol 2010, 55:1362-1369.
168. Mottillo S., Filion K.B., Genest J., et al. The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis. J Am Coll Cardiol 2010, 56:1113-1132.
169. Liu J., Grundy S.M., Wang W., et al. Ten-year risk of cardiovascular indidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J 2007, 153:552-558.
170. Donahoe S.M., Stewart G.C., McCabe C.H., et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007, 298:765-775.
171. Adiels M., Olofsson S.-O., Taskinen M.-R., Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidaemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1225-1236.
172. Scott R., O'Brien R., Fulcher G., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care 2009, 32:493-498.
173. IIanne-Parikka P., Eriksson J.G., Lindstrom J., et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish diabetes prevention study. Diabetes Care 2008, 31:805-807.
174. Ballantyne C.M., Olsson A.G., Cook T.J., et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001, 104:3046-3051. for the Scandinavian Simvastatin Survival Study.
175. Saha S.A., Arora R.R. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus-a pooled meta-analysis of randomized placebo-controlled clinical trials. Int J Cardiol 2009, 141:157-166.
176. Canner P.L., Furberg C.D., Terrin M.L., McGovern M.E. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005, 95:254-257.
177. Laing S.P., Swerdlow A.J., Slater S.D., et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003, 46:760-765.
178. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-prevenzione trial. Lancet 1999, 354:447-455. GISSI-Prevenzione Investigators.
179. Di Sciascio G., Patti G., Pasceri V., et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary interventions: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J Am Coll Cardiol 2009, 54:558-565.
180. Kjekshus J., Pedersen T., Olsson A., Færgeman O., Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997, 3:249-254.
181. Scirica B.M., Morrow D.A., Cannon C.P., et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 Study. J Am Coll Cardiol 2006, 47:2326-2331.
182. Kush K.K., Waters D.D., Bittner V., et al. Effects of high-dose atorvastatin on hospitalizations for heart failure. Subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007, 115:576-583.
183. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
184. Tavazzi L., Maggioni A.P., et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230. GISSI-HF Investigators.
185. Antonini-Canterin F., Zuppiroli A., Popescu B.A., et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol 2003, 92:1479-1482.
186. Peters M.J., Symmons D.P., McCarey D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
187. Gladman D.D., Ang M., Su L., et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009, 68:1131-1135.
188. Thorburn C.M., Ward M.M. Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:2519-2523.
189. Hyre A.D., Fox C.S., Astor B.C., Cohen A.J., Muntner P. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis 2007, 49:37-45.
190. de Jager D.J., Grootendorst D.C., Jager K.J., et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009, 302:1782-1789.
191. Tonelli M., Keech A., Shepherd J., et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005, 16:3748-3754.
192. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
193. Sandhu S., Wiebe N., Fried L.F., Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006, 17:2006-2016.
194. Douglas K., O'Malley P.G., Jackson J.L. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006, 145:117-124.
195. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621-627.
196. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997, 96:1398-1402.
197. Page R.L., Miller G.G., Lindenfeld J. Drug therapy in the heart transplant recipient part IV: drug-drug interactions. Circulation 2005, 111:230-239.
198. Navaneethan S.D., Perkovic V., Johnson D.W., et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev 2009, 2:CD005019.
199. Shaw S.M., Chaggar P., Ritchie J., et al. The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin. Transplantation 2009, 87:771-775.
200. Mc Dermott M.M., McDermott M.M., Mandapat A.L., et al. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. Arch Intern Med 2003, 163:2157-2162.
201. Hertzer N.R. Basic data concerning associated coronary disease in peripheral vascular patients. Ann Vasc Surg 1987, 1:616-620.
202. Maxwell H.G., Jepson R.G., Price J.F., Leng G.C. Lipid lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007, 4:CD000123.
203. Kang S., Wu Y., Li X. Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. Atherosclerosis 2004, 177:433-442.
204. Paraskevas K.I., Hamilton G., Mikhailidis D.P. Statins: an essential component in the management of carotid artery disease. J Vasc Surg 2007, 46:373-386.
205. Amarenco P., Labreuche J., Lavallée P., Touboul P.J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004, 35:2902-2909.
206. Tedeschi-Reiner E., Strozzi M., Skorić B., Reiner Ž. Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease. Am J Cardiol 2005, 96:1107-1109.
207. Paraskevas K.I., Liapis C.D., Hamilton G., Mikhailidis D.P. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?. Eur J Vasc Endovasc Surg 2006, 32:286-293.
208. Durazzo A.E., Machado F.S., Ikeoka D.T., et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004, 39:967-976.
209. Schouten O., Boersma E., Hoeks S.E., et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009, 361:980-989.
210. Amarenco P., Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009, 8:453-463.
211. Byington R.P., Davis B.R., Plehn J.F., et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) project. Circulation 2001, 103:387-392.
212. Glass T.R., Ungsedhapand C., Wolbers M., et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med 2006, 7:404-410.
213. 'Calza L., Manfredi R., Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003, 17:404-410.
214. Lundgren J.D., Battegay M., Behrens G., et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008, 9:72-81.
215. Van der Lee M., Sankatsing R., Schippers E., et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther 2007, 12:1127-1132.
216. Wohl D.A., Waters D., Simpson R.J., et al. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2008, 47:1105-1108.
217. Coodley G.O., Jorgensen M., Kirschenbaum J., et al. cholesterol in adults: a prospective, community-based practice initiative. Am J Med 2008, 121:604-610.
218. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis. BMJ 2003, 326:1423-1429.
219. McKenney J.M., Davidson M.H., Jacobson T.A., Guyton J.R. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006, 97:89C-95C. National Lipid Association Statin Safety Assessment Task Force.
220. Rasmussen J.N., Chong A., Alten D.A. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007, 297:177-186.
221. Wood D.A., Kotseva K., Connolly S., et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008, 371:1999-2012.
222. Reiner Z., Sonicki Z., Tedeschi-Reiner E. Public perceptions of cardiovascular risk factors: the PERCRO survey. Prev Med 2010, 51:494-496.
223. Reiner Z., Sonicki Z., Tedeschi-Reiner E. Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRODOC survey. Atherosclerosis 2010, 213:598-603.
224. Sloss E.M., Solomon D.H., Shekelle P.G., et al. Selecting target conditions for quality of care improvement in vulnerable older adults. J Am Geriatr Soc 2000, 48:363-369.